Enliven Therapeutics, Inc.
NASDAQ: ELVN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard A. Fair
- Employees
- 62
- Headquarters
- Boulder, United States
- IPO year
- 2020
- Market cap
- $3.4B
- Website
- https://www.enliventherapeutics.com
Loading ELVN…
Loading profile data…Frequently asked questions about ELVN
What does Enliven Therapeutics, Inc. (ELVN) do?
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myel...
Where does ELVN trade?
Enliven Therapeutics, Inc. (ELVN) trades on the NASDAQ Global Select.
What sector is ELVN in?
Enliven Therapeutics, Inc. (ELVN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enliven Therapeutics, Inc.?
Richard A. Fair is the chief executive officer of Enliven Therapeutics, Inc. (ELVN).
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. is headquartered in United States.
Does ELVN pay a dividend?
Enliven Therapeutics, Inc. (ELVN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ELVN go public?
Enliven Therapeutics, Inc. (ELVN) completed its initial public offering in 2020.